On October 10, 2022 InDex Pharmaceuticals Holding AB (publ) reported that the Board of Directors has named Jenny Sundqvist as new CEO (Press release, InDex Pharmaceuticals, OCT 10, 2022, View Source [SID1234621861]). Jenny comes from a position as Chief Commercial Officer at Isofol Medical AB and has broad experience from leading positions within the pharmaceutical industry. Johan Giléus, who has been acting CEO since April 2022, will continue as CFO in the company.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to welcome Jenny Sundqvist as the new CEO of InDex Pharmaceuticals. Jenny’s knowledge and experience in pharmaceutical development and business management will be of great benefit for further development of the company, and I also want to take the opportunity to thank Johan for his appreciated and valuable contributions to the company as acting CEO," said Wenche Rolfsen, Chairman of InDex Pharmaceuticals.
Jenny Sundqvist has an impressive track record of developing companies and creating value. She has broad experience in leading successful research organizations in combination with commercial experience in marketing of approved medications. Jenny has previously, among other things, worked as Chief Commercial Officer at Isofol Medical AB, been responsible for AstraZeneca’s global research portfolio in oncology, worked as Site Director for AstraZeneca’s research unit in Gothenburg and been global brand manager for AstraZeneca’s asthma product Symbicort.
"I am very grateful to have been entrusted by the Board of Directors to lead InDex on this exciting journey of taking cobitolimod through phase III and towards the market. I look forward to working with the Board of Directors and the competent employees at InDex with the goal of improving the quality of life for patients while building value for the shareholders," said Jenny Sundqvist.
Publication
This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication through the agency of the contact person set out above at 13:30 CET on October 10, 2022.